GERN · Geron
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $1.21
Note written ·
Price against the kill line
20.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $1.21, on record since 11 November 2026. The shares are down 36.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $1.21, the 50-day average of closes (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026
- Revenue, latest quarter ($M)
- 60.2
- Revenue, change on a year (%)
- +27.4
- Operating margin (%)
- 9.6
All filed numbers
What Geron reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 60.2 | +27.4 | 9.6 |
| first filed | 57.5 | +17.2 | −21.7 |
| first filed | 51.8 | +30.9 | 0.3 |
| first filed | 47.2 | +67.1 | −29.4 |
| first filed | 49.0 | +5459.6 | −25.4 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −47.8 | 1.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +1.0 |
| Operating cash flow ($M) | −90.5 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 69.2 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 46.0 |
| Inventory ($M) | 127 |
| Shareholders' equity ($M) | 227 |
| Market value ($M) | 623 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.7 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 11.6% of shares outstanding sold short, 9.9 days of average trading to cover, +1.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $19K |
The thesis
Geron Corporation's case now rests on one drug, RYTELO (imetelstat), in lower-risk myelodysplastic syndromes (MDS), a group of bone-marrow cancers, and the third-quarter report of 4 November 2026 showed it still growing: net product revenue of $60.1 million, up about 27% from $47.2 million a year earlier. The shares still closed at $0.97 on 10 November 2026, 50.0% below the 52-week high of $1.95, so the market is pricing the loss of the myelofibrosis program and the risk of stock issuance more heavily than the sales growth.
Geron ended the Phase 3 IMpactMF myelofibrosis trial on 28 October 2026 after its Data Monitoring Committee judged it unlikely to meet its overall-survival goal. The quarter that followed delivered revenue above the second quarter's $57.5 million, a profit of $1.4 million, and a cut to the 2026 operating expense range. The close on 10 November 2026 equals the post-halt close of 28 October 2026, so the report has not lifted the shares.
The story is well known: the trial halt and the quarterly report are both public, and the shares have drifted sideways since 28 October 2026 at $0.97. The three-month price change is −36.5% and the 14-day relative strength index is 36.9 (adjusted daily closes, 10 November 2026).
Bullish and bearish views on Geron Corporation
The bull case on Geron Corporation (GERN), in brief: revenue grew again. The bear case: growth in reported revenue slowed.
Bull case
- Revenue grew again. Net product revenue was $60.1 million in the third quarter, up about 5% from the second quarter and about 27% from a year earlier (Geron release, 4 November 2026). A news headline put it slightly short of a $60.353 million analyst estimate.
- Demand is accelerating. Geron said demand rose about 10% from the second quarter, against 5% in the second quarter and 6% in the first. Ordering accounts rose roughly 8% to about 1,700 (Geron release, 4 November 2026).
- The company turned profitable. Net income was $1.4 million, or $0.00 per share, against a net loss of $18.4 million a year earlier (Geron release, 4 November 2026).
- Spending guidance fell. Geron lowered 2026 total operating expenses to $220–230 million from $230–240 million and reiterated RYTELO revenue at the mid-to-high end of $220–240 million (Geron release, 4 November 2026).
- Cash rose. Cash, equivalents, restricted cash and marketable securities were $339.4 million at 30 September 2026, up from $326.9 million at 30 June 2026 (Geron release, 4 November 2026).
- Europe is opening. Geron expects a gated launch in Germany later in 2026 and in France in 2027 (Geron release, 4 November 2026).
Bear case
- Growth in reported revenue slowed. Sequential net revenue growth was about 5% in the third quarter against 11% in the second, even as demand grew faster (Geron release, 4 November 2026). The 10-Q expects gross-to-net deductions, the discount from list price to recognised revenue, in the low-to-mid twenties percent of gross revenue in the fourth quarter, against 21% in the first quarter and 13% a year earlier.
- Full-year guidance implies a step up. Nine-month revenue was $169.4 million (Geron 10-Q, 30 September 2026). Reaching the mid-to-high end of $220–240 million needs a fourth quarter above $60.1 million while deductions are expected to rise.
- Share count is climbing. Weighted-average basic shares were 672.3 million in the third quarter (Geron release, 4 November 2026), against 642.47 million outstanding in late August. Geron has a $150 million at-the-market stock-sale program filed in March 2026. Cash rose $12.5 million in a quarter with $1.4 million of net income, and the 10-Q's financing section shows how much came from stock sales.
- The pipeline option is gone. Discontinuing IMpactMF on 28 October 2026 removes the late-stage label expansion for imetelstat that Geron had described. Wedbush cut its target to $5 from $6 and Needham cut its target to $2.50 on 28 October 2026.
- The shares trade under $1.00. Closes were $0.97 on both 28 October 2026 and 10 November 2026. A sustained stretch under $1.00 would raise questions under Nasdaq's minimum-bid rule; no notice appears in the 4 November 2026 release.
Price setup
The adjusted close on 10 November 2026 was $0.97, 50.0% below the 52-week high of $1.95. The three-month price change is −36.5% and the 14-day relative strength index is 36.9, up from 26.8 on 28 October 2026 and no longer in oversold territory (adjusted daily closes).
The 28 October 2026 close of $0.97 is the post-halt reference point. The earnings release on 4 November 2026 produced a profit and lower expense guidance, and the shares ended the following week at the same close. That pattern shows sellers absorbing good news, with dilution risk the most likely weight.
The $0.85 level sits 12.4% below the latest close.
Catalysts ahead
- ~November 2026 (date unconfirmed): Geron participation in the Stifel 2026 Healthcare Conference. Management commentary on fourth-quarter demand, gross-to-net and European plans could address the revenue step-up that full-year guidance requires.
- ~31 December 2026 (company guidance): Germany launch of RYTELO and European strategy update. Europe is the main growth lever outside the US now that the myelofibrosis trial has ended.
- 12 December 2026: American Society of Hematology annual meeting opens; six Geron RYTELO abstracts. New clinical data in lower-risk MDS can support the demand story.
- ~February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether RYTELO revenue reached the mid-to-high end of the $220–240 million guidance and what the share count looks like.
What would change the view
A daily close above $1.21, the 50-day average of closes (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Geron trades as a single-product commercial-stage oncology company, so its moves follow RYTELO sales data and financing news more than the broader biotech index. Small-cap biotech sentiment and funding conditions matter at sub-$1 share prices, where stock sales issue more shares per dollar raised. The 28 October 2026 session shows the shares can move sharply on pipeline news that has no connection to current sales.
The evidence, claim by claim (8)
- Q3 2026 RYTELO net product revenue $60.1M, up about 27% from $47.2M in Q3 2025 and about 5% from Q2; demand up about 10% QoQ. Geron Q3 2026 results release (8-K Ex. 99.1) · as of
- Q3 2026 net income $1.4M, $0.00 per share, versus net loss $18.4M, $(0.03) per share, in Q3 2025. Geron Q3 2026 results release (8-K Ex. 99.1) · as of
- Cash, equivalents, restricted cash and marketable securities of $339.4M at 9/30/2026 versus $326.9M at 6/30/2026. Geron Q3 2026 results release · as of
- 2026 total operating expenses guidance lowered to $220–230M from $230–240M; RYTELO net revenue guidance reiterated at the mid-to-high end of $220–240M. Geron Q3 2026 results release · as of
- Ordering accounts rose roughly 8% to about 1,700 in Q3 2026. Geron Q3 2026 results release · as of
- Weighted-average basic shares were 672.3M and diluted 674.1M in Q3 2026. Geron Q3 2026 results release · as of
- Geron discontinued the Phase 3 IMpactMF trial after a Data Monitoring Committee judged it unlikely to meet its overall-survival endpoint. Geron announcement, reported by Yahoo Finance and GuruFocus · as of
- Six Geron abstracts accepted at the 68th ASH Annual Meeting, 12–16 December 2026. Geron press release via Finviz · as of
Sources
Related · shared themes
ORKA
Oruka Therapeutics
Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
XNCR
Xencor
Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
See also · stocks to watch